Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $4.6600 (0.32%) ($4.6600 - $4.6600) on Mon. Jan. 10, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5% (three month average) | RSI | 38 | Latest Price | $4.6600(0.32%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -3.2% a day on average for past five trading days. | Weekly Trend | AUTL declines -5.2% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Value stock sell-off for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) XBI(66%) IBB(60%) IBUY(58%) ARKG(56%) ARKK(54%) | Factors Impacting AUTL price | AUTL will decline at least -2.5% in a week (0% probabilities). VIXM(-43%) VXX(-34%) TLT(-25%) SHY(-22%) TIP(-20%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.5% (StdDev 5%) | Hourly BBV | -0.6 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-6.94(-248.93%) | Resistance Level | $5.26 | 5 Day Moving Average | $4.85(-3.92%) | 10 Day Moving Average | $5.04(-7.54%) | 20 Day Moving Average | $5.26(-11.41%) | To recent high | -33.9% | To recent low | 0.3% | Market Cap | $243m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |